SynDevRx Clinical Drug Candidate SDX-7320 Offsets Hyperglycemia Caused by PI3K/Akt/mTOR Cancer Therapies and Restores Insulin Sensitivity, Preclinical Studies Show

CAMBRIDGE, Mass. – October 21, 2020 – SynDevRx, Inc., a clinical-stage oncology company, announces the completion of a series of preclinical studies demonstrating that its anti-cancer drug candidate, SDX-7320, inhibits PI3K/Akt inhibitor-induced hyperglycemia and subsequent hyperinsulinemia in normal mice and inhibits tumor growth in multiple models of HR+ breast cancer.

Read Press Release

Previous Post
Recombinetics Inc. Merges with Makana Therapeutics to Accelerate Xenotransplantation
Next Post
Scorpion Therapeutics debuts with $108M to ‘put the sting in cancer’

Leave a Reply

Your email address will not be published. Required fields are marked *

Fill out this field
Fill out this field
Please enter a valid email address.

Menu